Marksans Pharma Limited has achieved a key milestone as its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets.
In the exchange filing, the company shared, “Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA.”
Baclofen is widely used to treat muscle spasms caused by conditions such as multiple sclerosis, spinal cord injuries, and neurological disorders. With this approval, Marksans Pharma strengthens its footprint in the UK pharmaceutical market, reinforcing its commitment to providing high-quality and affordable medicines globally.
